

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

JMSU-1

RRID:CVCL_2081

Type: Cell Line

Proper Citation

RRID:CVCL_2081

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2081

Proper Citation: RRID:CVCL_2081

Description: Cell line JMSU-1 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Bladder carcinoma

Defining Citation: [PMID:7483139](#), [PMID:22460905](#), [PMID:24035680](#), [PMID:24367658](#), [PMID:26589293](#), [PMID:29732388](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#)

Comments: Karyotypic information: Has lost chromosome Y., Population: Japanese., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: JMSU-1

Synonyms: JMSU1

Cross References: CLO:CLO_0050846, ArrayExpress:E-MTAB-2770, BioGRID_ORCS_Cell_line:626, BioSample:SAMN03472026, BioSample:SAMN03473570, BioSample:SAMN10988102, cancercellines:CVCL_2081, Cell_Model_Passport:SIDM01587, Cosmic:1285120, Cosmic:2050446, Cosmic:2057451, Cosmic:2444245, Cosmic:2686098, DepMap:ACH-000753, DSMZ:ACC-505, DSMZCellDive:ACC-505, FANTOM5_SSTAR:10492-107B6, GEO:GSM887187, GEO:GSM888260, IARC_TP53:28279, LiGeA:CCLE_366, PharmacDB:JMSU1_710_2019, Progenetix:CVCL_2081, RCB:RCB2227,

Wikidata:Q54899011

ID: CVCL_2081

Record Creation Time: 20220427T220651+0000

Record Last Update: 20260905T180914+0000

Ratings and Alerts

No rating or validation information has been found for JMSU-1.

No alerts have been found for JMSU-1.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang K, et al. (2025) Molecular mechanisms of CAND2 in regulating SCF ubiquitin ligases. Nature communications, 16(1), 1998.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Subbiah V, et al. (2023) RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. Cancer discovery, 13(9), 2012.

Hong AL, et al. (2019) Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition. eLife, 8.

Halstead AM, et al. (2017) Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation. eLife, 6.